JP2016514159A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514159A5
JP2016514159A5 JP2016502219A JP2016502219A JP2016514159A5 JP 2016514159 A5 JP2016514159 A5 JP 2016514159A5 JP 2016502219 A JP2016502219 A JP 2016502219A JP 2016502219 A JP2016502219 A JP 2016502219A JP 2016514159 A5 JP2016514159 A5 JP 2016514159A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
compound according
heteroaryl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502219A
Other languages
English (en)
Japanese (ja)
Other versions
JP6276378B2 (ja
JP2016514159A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026710 external-priority patent/WO2014151945A1/en
Publication of JP2016514159A publication Critical patent/JP2016514159A/ja
Publication of JP2016514159A5 publication Critical patent/JP2016514159A5/ja
Application granted granted Critical
Publication of JP6276378B2 publication Critical patent/JP6276378B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502219A 2013-03-14 2014-03-13 ヒストンデメチラーゼ阻害剤 Expired - Fee Related JP6276378B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783563P 2013-03-14 2013-03-14
US61/783,563 2013-03-14
PCT/US2014/026710 WO2014151945A1 (en) 2013-03-14 2014-03-13 Histone demethylase inhibitors

Publications (3)

Publication Number Publication Date
JP2016514159A JP2016514159A (ja) 2016-05-19
JP2016514159A5 true JP2016514159A5 (OSRAM) 2017-02-16
JP6276378B2 JP6276378B2 (ja) 2018-02-07

Family

ID=51529949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502219A Expired - Fee Related JP6276378B2 (ja) 2013-03-14 2014-03-13 ヒストンデメチラーゼ阻害剤

Country Status (7)

Country Link
US (5) US9133166B2 (OSRAM)
EP (1) EP2969007B1 (OSRAM)
JP (1) JP6276378B2 (OSRAM)
AU (1) AU2014236711A1 (OSRAM)
CA (1) CA2903081A1 (OSRAM)
ES (1) ES2731773T3 (OSRAM)
WO (1) WO2014151945A1 (OSRAM)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US10414750B2 (en) 2014-07-03 2019-09-17 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
MX2017003464A (es) 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP2016089002A (ja) * 2014-10-31 2016-05-23 出光興産株式会社 ベンゾフラノチオフェン骨格を有するモノマー及びポリマー、及びそのポリマーを用いた有機薄膜太陽電池材料
WO2016112251A1 (en) * 2015-01-09 2016-07-14 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US20190055212A1 (en) * 2016-02-16 2019-02-21 Stephen Gwaltney Histone demethylase inhibitors
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017161033A1 (en) * 2016-03-15 2017-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP6746776B2 (ja) 2016-09-02 2020-08-26 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体調節剤化合物
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
IL308894A (en) 2016-10-14 2024-01-01 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
CN106543092B (zh) * 2016-10-14 2019-05-17 华东师范大学 1,5-二芳香基-1,2,4-三氮唑类化合物及其制药用途
TW202510891A (zh) 2017-01-31 2025-03-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
MY196582A (en) 2018-02-13 2023-04-19 Gilead Sciences Inc PD-1/PD-L1 Inhibitors
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’-環二核苷酸
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
PL3873903T3 (pl) 2018-10-31 2024-05-20 Gilead Sciences, Inc. Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
JP7237311B2 (ja) * 2019-06-06 2023-03-13 京都府公立大学法人 化合物、医薬組成物、kdm5c阻害剤及び抗うつ剤
US20210009718A1 (en) 2019-06-25 2021-01-14 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
EP4567109A3 (en) 2019-12-06 2025-09-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
TW202421168A (zh) 2020-03-20 2024-06-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20250099113A (ko) 2022-09-09 2025-07-01 이노보 테라퓨틱스 인코포레이티드 CK1α 및 DUAL CK1α/GSPT1 분해 화합물
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1058549A4 (en) 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
PL366114A1 (en) 2000-10-26 2005-01-24 Tularik Inc. Antiinflammation agents
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2632444A1 (en) 2005-12-19 2007-06-28 Boehringer Ingelheim International Gmbh Use of aminoalcohol derivatives for the treatment of overactive bladder
TWI386405B (zh) * 2006-09-05 2013-02-21 咪唑衍生物
BRPI0807717A2 (pt) * 2007-04-20 2014-05-20 Deciphera Pharmaceuticals Llc Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
GB0818907D0 (en) 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors
EP2451790A4 (en) * 2009-07-07 2012-12-26 Anthem Biosciences Private Ltd INHIBITORS OF HISTONE DEACETYLASE
EP2499139B1 (en) 2009-11-10 2013-12-11 Pfizer Inc N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP5725475B2 (ja) * 2010-01-21 2015-05-27 公立大学法人名古屋市立大学 ヒドロキサム酸誘導体及びそれを用いたhdac8阻害剤
GB201112607D0 (en) 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
CN102775368B (zh) * 2011-05-10 2016-08-17 上海驺虞医药科技有限公司 一类噻唑类化合物及其制备方法和用途
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
MX2017003464A (es) 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.

Similar Documents

Publication Publication Date Title
JP2016514159A5 (OSRAM)
JP2016501882A5 (OSRAM)
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
JP2016503799A5 (OSRAM)
JP2017527590A5 (OSRAM)
JP2013537203A5 (OSRAM)
JP2016505614A5 (OSRAM)
CY1118340T1 (el) Αναστολεις κινασης
JP2015024998A5 (OSRAM)
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
JP2016503793A5 (OSRAM)
JP2013532687A5 (OSRAM)
JP2018531941A5 (OSRAM)
JP2011529054A5 (OSRAM)
JP2011518833A5 (OSRAM)
JP2017501237A5 (OSRAM)
JP2013532130A5 (OSRAM)
JP2017514910A5 (OSRAM)
JP2015199738A5 (OSRAM)
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
JP2014526533A5 (OSRAM)
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
JP2016532632A5 (OSRAM)
JP2016530242A5 (OSRAM)
JP2018145180A5 (OSRAM)